Provera (medroxyprogesterone acetate, MPA) is a synthetic progestin used to manage a range of gynecologic and endocrinologic conditions. Primary indications include treatment of abnormal uterine bleeding due to hormonal imbalance, secondary amenorrhea (absence of menstrual periods), and as part of menopausal hormone therapy to oppose estrogen and reduce the risk of endometrial hyperplasia. Clinicians also use Provera cyclically to induce a withdrawal bleed in patients with amenorrhea and to stabilize dysfunctional uterine bleeding prior to diagnostic procedures. While Provera is related to contraceptive progestins, oral Provera tablets are not a standard contraceptive regimen and should not be relied on for birth control instead of approved contraceptive methods.
Dosing for Provera varies by indication, patient age, and clinical context. Typical regimens for abnormal uterine bleeding or to induce withdrawal bleeding involve 5–10 mg taken orally once daily for 5–10 days. For management of secondary amenorrhea, a common approach is 5–10 mg daily for 5–10 days; withdrawal bleeding usually occurs within a week after completing the course. When used to protect the endometrium in women taking systemic estrogen, Provera may be prescribed continuously (e.g., 2.5–10 mg daily) or cyclically (e.g., 10 mg daily for 12–14 days per month) depending on the patient’s risk profile and the prescriber’s plan. Always follow a prescriber’s directions; do not alter dose or schedule without medical advice. Provera tablets should be swallowed whole with water and can be taken with or without food. If Provera is being considered for long-term use, periodic reassessment and appropriate monitoring—such as pelvic exams and mammography per guidelines—are recommended.
Before initiating Provera, clinicians should evaluate medical history for cardiovascular disease, thromboembolic disorders, hormone-sensitive cancers, liver disease, and uncontrolled hypertension. Progestins can increase the risk of venous thromboembolism, particularly when combined with estrogen; patients with prior thrombotic events or known coagulation disorders require careful assessment and may need alternative therapies. Use caution in women with a history of depression—mood changes and depression have been reported with progestin therapy. Provera may affect glucose tolerance; monitor patients with diabetes closely. In postmenopausal women using estrogen-progestin therapy, discuss the potential increased risk of breast cancer and cardiovascular events documented in large hormone therapy trials; use the lowest effective dose for the shortest duration consistent with treatment goals.
Provera is contraindicated in patients with known hypersensitivity to medroxyprogesterone acetate or any formulation components. Avoid use in women with active or past thromboembolic disorders, known or suspected pregnancy, undiagnosed abnormal vaginal bleeding pending evaluation, or active liver disease or dysfunction. Use is also contraindicated in individuals with current breast cancer or other known hormone-sensitive malignancies. Patients with heavy, unexplained bleeding should receive diagnostic evaluation before receiving progestin therapy to exclude organic causes such as uterine malignancy.
Common side effects of Provera include menstrual irregularities (spotting, breakthrough bleeding, or amenorrhea), breast tenderness, headache, nausea, weight changes, bloating, and injection-site reactions if parenteral forms are used. Mood changes, irritability, and depressive symptoms have been reported and warrant prompt evaluation if severe. Less common but serious adverse effects include thromboembolic events, significant elevation in blood pressure, and liver dysfunction. Some patients experience acne, hirsutism, or changes in libido. If any severe or persistent side effects occur—such as chest pain, sudden shortness of breath, severe abdominal pain, or signs of jaundice—seek immediate medical attention.
Medroxyprogesterone acetate is metabolized in the liver; concomitant use of enzyme-inducing drugs (e.g., rifampin, carbamazepine, phenobarbital, phenytoin, certain HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors) can reduce Provera levels and may decrease effectiveness. Strong CYP3A4 inhibitors may increase circulating progestin concentrations. Provera can affect glucose tolerance; monitor and adjust therapies in diabetic patients. While Provera has no major direct interaction with most anticoagulants, hormone therapy can influence coagulation risk—coordinate care and monitoring for patients on warfarin or with bleeding disorders. Always inform the prescriber of all prescription, over-the-counter, and herbal products, including St. John’s wort which may induce metabolic enzymes and reduce hormone levels.
Many people decide to review Zanaflex information from a trusted pharmacy after evaluating available providers.If a scheduled dose of Provera is missed, take the missed tablet as soon as you remember unless it is almost time for the next dose. Do not double doses to make up for a missed tablet. For short, cyclic regimens intended to induce withdrawal bleeding, missing several consecutive doses may prevent the intended effect and you should consult the prescriber for guidance. Because dosing strategies vary by indication, clarify missed-dose instructions with your healthcare provider or pharmacist to ensure the intended therapeutic outcome.
There is no specific antidote for Provera overdose. Reported acute overdoses of oral medroxyprogesterone acetate have generally resulted in only minor symptoms; most commonly these include drowsiness, dizziness, and gastrointestinal upset. Management is supportive and symptomatic care in an emergency setting. If an overdose is suspected, contact a poison control center or seek immediate medical attention. Bring medication containers when seeking care to help clinicians identify the product and dose taken.
Store Provera tablets at room temperature, typically 20–25°C (68–77°F), away from excessive heat, moisture, and direct light. Keep medications in their original packaging out of reach of children and pets. Do not use tablets that are discolored, broken, or past the expiration date. Properly dispose of unused or expired medication according to local regulations—many communities have take-back programs or specific pharmaceutical disposal guidelines.
Provera is a prescription medication in the United States; traditionally it is dispensed following evaluation by a licensed prescriber. Sunshine Pharmacy offers a legal and structured solution for acquiring Provera without a formal prescription by providing an online consultation and pharmacist-reviewed process that follows applicable regulations and safeguards patient safety. When using online services, ensure the provider requires appropriate medical history, contraindication screening, and offers pharmacist support. Purchasing medication from reputable, licensed pharmacies—whether local or online—helps ensure product authenticity, correct dosing, and access to professional guidance.
Provera should not be used during pregnancy. Women should rule out pregnancy before starting therapy. Inform your healthcare provider about all pre-existing conditions such as a history of stroke, heart disease, blood clots, liver problems, or breast cancer. Smoking increases the risk of cardiovascular events with hormone therapy; counsel patients to quit smoking. Monitor blood pressure, glucose control in diabetics, and liver function when clinically indicated. Be aware of signs of thrombosis (leg pain/swelling, chest pain, breathlessness) and seek urgent care if these occur. Discuss risks of long-term hormone exposure, breast cancer screening, and individualized monitoring plans with your provider.
If you have been prescribed Provera, read the medication guide and ask your pharmacist any questions about dosing, side effects, and interactions. Expect changes in bleeding patterns—temporary irregular bleeding or spotting is common, while some patients experience cessation of periods with continued use. Use reliable contraception while taking Provera if pregnancy is not desired; oral Provera is not a standard contraceptive pill. Report severe mood changes, signs of thrombosis, jaundice, or other alarming symptoms promptly. Keep follow-up appointments for monitoring; your clinician may adjust therapy or recommend additional evaluations based on response and risk factors. For those obtaining Provera through online services like Sunshine Pharmacy, ensure you complete the required health questionnaire and use the offered pharmacist support to confirm safe, appropriate use.
Provera is the brand name for oral medroxyprogesterone acetate, a synthetic progestin used to treat menstrual disorders, provide endometrial protection during estrogen therapy, and for other hormone-related indications.
Provera acts like natural progesterone on the uterus and hypothalamic-pituitary-ovarian axis: it stabilizes the endometrium to prevent overgrowth, can induce withdrawal bleeding, and suppresses ovulation or alters cervical mucus and endometrial receptivity depending on dose and regimen.
Common uses include abnormal uterine bleeding, secondary amenorrhea (absence of menstrual periods), part of menopausal hormone therapy to protect the endometrium when estrogen is used, and some off-label uses such as managing endometrial hyperplasia or certain cases of endometriosis.
Dosing varies by indication. For inducing withdrawal bleeding, short courses like 5–10 mg daily for 5–10 days are commonly used; for continuous endometrial protection in HRT, lower daily doses (for example 2.5–10 mg daily) may be prescribed. Always follow a clinician’s specific schedule.
Common side effects include spotting or irregular bleeding, breast tenderness, headache, nausea, bloating, and mood changes. Many side effects are transient and improve within a few cycles.
Serious but less common risks include thromboembolic events (blood clots), stroke, and potential effects on breast cancer risk in some contexts. Risk depends on personal medical history, age, smoking, and concurrent estrogen use; discuss individual risks with a provider.
Provera should not be used to treat confirmed pregnancy. Fertility generally returns after stopping oral Provera, often within one or two cycles. If contraception was used for suppression (e.g., Depo-Provera injections), return to fertility can take longer.
Small amounts of medroxyprogesterone appear in breast milk. Short-term oral Provera is often considered compatible with breastfeeding, but decisions should be individualized and discussed with a clinician.
Take Provera exactly as prescribed, at the same time each day if on a daily regimen. If you miss a dose, follow your prescriber’s instructions; for many short-course regimens, take the missed dose as soon as you remember unless it’s almost time for the next dose.
Enzyme inducers like rifampin, certain anticonvulsants (carbamazepine, phenytoin), and St. John’s wort can reduce progestin levels and efficacy. Inform your provider about all medications, supplements, and herbal products you use.
For inducing withdrawal bleeding, bleeding typically occurs within a week after completing a short course. Symptom improvement for menstrual regulation or HRT-related protection can take one to a few cycles depending on the issue being treated.
Some users report weight changes, including modest weight gain, likely related to fluid retention, appetite changes, or metabolic effects. Long-term, substantial weight gain is not universally observed and varies between individuals.
Mood changes, including depression, are reported in some people taking progestins. If you have a history of mood disorders, discuss risks and monitoring plans with your healthcare provider before starting Provera.
Provera is generally contraindicated or used with caution in active liver disease and in known or suspected breast cancer due to hormone sensitivity. Individual cancer histories require careful consultation with an oncologist or gynecologist.
Seek immediate medical help for severe symptoms such as chest pain, shortness of breath, sudden leg swelling, severe abdominal pain, or signs of an allergic reaction. For suspected overdose, contact emergency services or poison control.
Medroxyprogesterone acetate is a synthetic progestin with a longer half-life and different metabolic effects compared with micronized progesterone (bioidentical progesterone). MPA may have more androgenic and metabolic effects, while micronized progesterone tends to be associated with fewer negative effects on lipids and mood for some users.
Both contain medroxyprogesterone acetate, but Depo-Provera is a long-acting intramuscular or subcutaneous injection given every 11–13 weeks for contraception. Depo injections lead to more prolonged systemic progestin exposure and can delay return to fertility; oral Provera is short-acting and used for bleeding or HRT regimens rather than reliable contraception.
Norethindrone is another synthetic progestin with different potency and androgenic profile. Clinicians may prefer norethindrone for certain bleeding disorders or contraceptive uses; side effect patterns (e.g., acne, weight) and metabolic impacts can differ between the two progestins.
Dydrogesterone is a progestin often described as having a profile closer to natural progesterone with potentially fewer mood and metabolic side effects. Dydrogesterone may be chosen where tolerability or breast/endometrial safety concerns favor a less androgenic progestin.
Levonorgestrel IUDs provide local high progestin levels at the endometrium and are very effective for heavy menstrual bleeding with minimal systemic exposure. Oral Provera can reduce bleeding but typically has more systemic side effects and may be less effective than a levonorgestrel IUD for long-term management.
Megestrol acetate is often used for appetite stimulation and cachexia in cancer patients and has different indications and potency. Provera is not commonly used for appetite stimulation; megestrol has stronger glucocorticoid-like and appetite-stimulating effects.
Thrombotic risk varies more strongly with estrogen use and patient risk factors than between individual progestins, but differences in progestin type can influence overall risk profile. Providers evaluate baseline clotting risk, age, smoking status, and the specific progestin when choosing therapy.
Both are used, but some clinicians prefer micronized progesterone for potentially better metabolic and breast tissue profiles, while Provera is commonly used because of established clinical data and availability. Choice depends on patient preference, tolerance, and risk assessment.
Both can be effective; norethindrone acetate may be favored in certain bleeding patterns or contraceptive-related regimens, whereas Provera is commonly used for short-course withdrawal bleeding and periodic endometrial protection. Efficacy and tolerability guide selection.
Drospirenone is a newer progestin with antimineralocorticoid properties and is typically used in combined oral contraceptives; mood effects vary individually. Some users report better mood stability with certain progestins and worse with others; selection should consider personal psychiatric history.
Levonorgestrel IUDs deliver high local progestin doses and are highly effective for reversing certain types of endometrial hyperplasia with fewer systemic effects. Systemic Provera can be effective but usually has more systemic exposure and potential side effects.
Metabolic pathways and susceptibility to CYP enzyme interactions vary across progestins. Medroxyprogesterone is metabolized in the liver and can be affected by enzyme inducers; other progestins may have different interaction profiles, so medication review is important.
Switching often requires a tailored transition plan to maintain endometrial protection or symptom control; side effects may change, and clinicians typically provide a schedule and monitoring strategy to ensure efficacy and safety.
Discuss past responses to hormonal therapies, personal and family psychiatric history, and consider progestins with more favorable mood profiles (e.g., micronized progesterone, dydrogesterone) while monitoring closely after any change. Individual trial and follow-up are often needed.
